A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

A Randomized, Positive and Placebo-Controlled Trial to Evaluate the Effects of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

This will be a Phase 1, single-center, 2-part study in healthy subjects. Parts 1 and 2 need to be conducted in sequential order.

Study Overview

• Status: Terminated
• Conditions: Cardiac Repolarization
• Intervention / Treatment: Drug: Placebo; Drug: Moxifloxacin (positive control); Drug: Milademetan

Detailed Description

Part 1 will enroll up to 3 cohorts of 6 healthy adult subjects to receive a single dose. The total duration of participation from the Screening visit to the follow-up will be up to 7 weeks (up to 45 days).

Part 2 of this study will randomize approximately 32 subjects. The total duration of participation from the Screening visit to the follow-up will be up to 8 weeks (up to 55 days).

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • Victoria
    • Melbourne, Victoria, Australia, 3004
      • Nucleus Network Melbourne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Is capable of understanding informed consent and is willing and able to provide written informed consent.
2. Is willing to comply with all protocol procedures.
3. Healthy, male, nonsmoking (for at least 90 days) subjects from 18 through 55 years of age, inclusive, at Screening, and healthy, female, nonsmoking (for at least 90 days) subjects of nonchildbearing potential from 18 through 55 years of age, inclusive, at Screening.
4. Body weight > 50 kg, body mass index between 18.0 and 30 kg/m2, inclusive.

Exclusion Criteria:

1. Past or present clinically relevant systemic disease as judged by the Investigator including, but not limited to, clinically relevant medical abnormalities such as psychiatric, neurologic, pulmonary, respiratory, cardiac, gastrointestinal, genitourinary, renal, hepatic, metabolic, endocrinologic, hematological, or autoimmune disorders making implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator.
2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
3. Knowledge of any kind of cardiovascular disorder/condition/procedure known to increase the possibility of QT prolongation or a history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, hypomagnesemia, congenital long QT syndrome, or family history of long QT syndrome, or Brugada syndrome), or cardiac conduction disorders.
4. Resting supine systolic blood pressure greater than 140 mm Hg; resting supine diastolic blood pressure greater than 90 mm Hg at Screening or Day -1. Blood pressure measurements may be repeated once at the discretion of the Investigator.
5. Resting supine HR less than 45 beats per minute or greater than 100 beats per minute at Screening or Day -1 (may be repeated once at the discretion of the Investigator). Minor deviations are acceptable if considered to be of no clinical significance by the Investigator.

6. Abnormal 12-lead ECG at Screening or Day -1 (a single repeat is allowed), including:

   1. QTcF > 450 msec
   2. QRS > 110 msec
   3. PR > 200 msec
   4. Second or third-degree atrioventricular block
7. Any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant at Screening or Day -1.
8. Dosing in another clinical trial within the last 30 days (or 5 half-lives, whichever is longer) prior to Day -1.
9. Family history of unexplainable sudden death at < 50 years of age.
10. History of unexplained loss of consciousness, unexplained syncope, unexplained irregular heartbeats or palpitations, clinically significant head injury, or near drowning with hospital admission.
11. Known allergic reactions to moxifloxacin (for Part 2 only) or any study medication or history of tendonitis or tendon rupture as a result of moxifloxacin or any other quinolone type drug use (for Part 2 only).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: A = Placebo (negative control); Dosage Form: Capsules Route of Administration: Oral The placebo and milademetan will be identical in appearance.	Drug: Placebo; Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
Active Comparator: B = Moxifloxacin (positive control); Dosage Form: Tablets Route of Administration: Oral Dosage: 400 mg	Drug: Moxifloxacin (positive control); Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
Experimental: C = Milademetan; Drug: Milademetan Dosage: Part 1: 300, 330, 360 mg. Part 2: 260 mg single oral dose or higher, as determined in Part 1.	Drug: Milademetan; Participants will receive a single dose of Milademetan on Day 1 for part 1 Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events (AEs)	The intensity of all AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0	Part 1:Up to 15 days
Number of participants with adverse events (AEs)	The intensity of all AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0	Part 2: Up to 25 days
Incidence of laboratory abnormalities based on hematology test results	Hematocrit, Hemoglobin, Mean cell hemoglobin	Part 1:Up to 15 days
Incidence of laboratory abnormalities based on hematology test results	Hematocrit, Hemoglobin, Mean cell hemoglobin	Part 2: Up to 25 days
Incidence of laboratory abnormalities based on clinical chemistry test results	Alanine aminotransferase, Albumin, Alkaline phosphatase, Aspartate aminotransferase	Part 1:Up to 15 days
Incidence of laboratory abnormalities based on clinical chemistry test results	Alanine aminotransferase, Albumin, Alkaline phosphatase, Aspartate aminotransferase	Part 2: Up to 25 days
Incidence of laboratory abnormalities based on urinalysis test results	Bilirubin, color and appearance, glucose, ketones, protein	Part 1:Up to 15 days
Incidence of laboratory abnormalities based on urinalysis test results	Bilirubin, color and appearance, glucose, ketones, protein	Part 2: Up to 25 days
Vital signs measurements	Supine systolic blood pressure in mmHg and supine diastolic blood pressure in mmHg	Part 1:Up to 15 days
Vital signs measurements	Supine systolic blood pressure in mmHg and supine diastolic blood pressure in mmHg	Part 2: Up to 25 days
Change from baseline in QT interval of the ECG	QT interval measured in msec	Part 1:Up to 15 days
Change from baseline in QT interval of the ECG	QT interval measured in msec	Part 2: Up to 25 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Observed maximum plasma concentration (Cmax)	observed maximum plasma concentration in ng/ml	Part 1:Up to 15 days
Observed maximum plasma concentration (Cmax)	observed maximum plasma concentration in ng/ml	Part 2: Up to 25 days
Time to observed maximum concentration (Tmax)	time to observed maximum concentration in hour	Part 1:Up to 15 days
Time to observed maximum concentration (Tmax)	time to observed maximum concentration in hour	Part 2: Up to 25 days
area under the time-concentration curve from time zero to the time of the last quantifiable concentration (AUC0-tlast)	Expressed as ng/ml x hr	Part 1:Up to 15 days
area under the time-concentration curve from time zero to the time of the last quantifiable concentration (AUC0-tlast)	Expressed as ng/ml x hr	Part 2: Up to 25 days

Collaborators and Investigators

• Sponsor: Rain Oncology Inc

Study record dates

Study Major Dates

• Study Start (Actual): April 17, 2023
• Primary Completion (Actual): June 8, 2023
• Study Completion (Actual): June 8, 2023

Study Registration Dates

• First Submitted: January 29, 2023
• First Submitted That Met QC Criteria: March 6, 2023
• First Posted (Actual): March 7, 2023

Study Record Updates

• Last Update Posted (Actual): August 8, 2023
• Last Update Submitted That Met QC Criteria: August 4, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Moxifloxacin
• Other Study ID Numbers: RAIN-3258

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes